Caroline has served as a member of PhaseBio’s board of directors since July 2018. She is a consultant providing strategy advisory services for biopharmaceutical companies and has more than 25 years of experience in the biotechnology industry. She has held numerous executive roles, most recently as co-founder, Chief Financial Officer and Chief Business Officer of Achieve Life Sciences, Inc. (acquired by OncoGenex). Earlier in her career, Caroline served as Chief Financial Officer of Tobira Therapeutics, Inc., Corcept Therapeutics, Inc. and Poniard Pharmaceuticals, Inc. Caroline serves on the boards of directors of Aptose Biosciences, Inc. and CymaBay Therapeutics, Inc. She is a founding board member of the Global Genes Project, a leading rare disease patient advocacy organization, a member of the National Advisory Committee of the Translational Genomics Research Institute’s Center for Rare Childhood Disorders and a co-founder of KCNQ2 Cure Alliance, a non-profit advancing research for the rare disease KCNQ2 epileptic encephalopathy. Caroline received a BA from the University of California, Berkeley and an MBA and MS from Carnegie Mellon University.